J. Goldman & CO LP Atara Biotherapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding ATRA
# of Institutions
7Shares Held
2.89MCall Options Held
0Put Options Held
0-
Kpcb Xv Associates, LLC1.88MShares$29.2 Million19.79% of portfolio
-
Antipodean Advisors LLC New York, NY1MShares$15.6 Million8.12% of portfolio
-
Ifp Advisors, Inc4.5KShares$69,9750.0% of portfolio
-
American Portfolios Advisors Holbrook, NY4.5KShares$69,9750.0% of portfolio
-
Wipfli Financial Advisors Llc,3.08KShares$47,8780.0% of portfolio
About Atara Biotherapeutics, Inc.
- Ticker ATRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,362,304
- Market Cap $1.47B
- Description
- Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...